MAP2K7 and melanoma: Furthermore, a phase I trial study has demonstrated the potential synergy between anti-PD-1 inhibitor and other BRAF/MEK inhibitors in treating patients with BRAF-mutant stage IIIC-IV melanoma (NCT03543969).